Form 4: Jazz Pharmaceuticals Executive Sells Shares
Insider Transaction (Form 4)
Robert Iannone, EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals plc, sold 76,921 shares of common stock on August 27, 2026.
Summary
- Option exercise/conversion: acquired 26,116 Ordinary Shares at $113.10 ($2,953,720) on August 27, 2026; holds 111,223 after (Direct).
- Option exercise/conversion: acquired 884 Ordinary Shares at $113.10 ($99,980) on August 27, 2026; holds 112,107 after (Direct).
- Option exercise/conversion: acquired 27,584 Ordinary Shares at $137.12 ($3,782,318) on August 27, 2026; holds 139,691 after (Direct).
- Option exercise/conversion: acquired 2,916 Ordinary Shares at $137.12 ($399,842) on August 27, 2026; holds 142,607 after (Direct).
- Open-market sale: disposed of 18,187 Ordinary Shares at $247.86 ($4,507,781) on August 27, 2026; holds 124,420 after (Direct).
- Open-market sale: disposed of 11,423 Ordinary Shares at $248.67 ($2,840,516) on August 27, 2026; holds 112,997 after (Direct).
- Open-market sale: disposed of 18,113 Ordinary Shares at $250.02 ($4,528,572) on August 27, 2026; holds 94,884 after (Direct).
- Open-market sale: disposed of 19,639 Ordinary Shares at $250.60 ($4,921,596) on August 27, 2026; holds 75,245 after (Direct).
- Open-market sale: disposed of 9,259 Ordinary Shares at $251.95 ($2,332,804) on August 27, 2026; holds 65,986 after (Direct).
- Open-market sale: disposed of 300 Ordinary Shares at $252.76 ($75,828) on August 27, 2026; holds 65,686 after (Direct).
- Option exercise/conversion: disposed of 884 Incentive Stock Option (right to buy) on August 27, 2026 (Direct).
- Option exercise/conversion: disposed of 2,916 Incentive Stock Option (right to buy) on August 27, 2026 (Direct).
- Option exercise/conversion: disposed of 26,116 Non-Qualified Stock Option (right to buy) on August 27, 2026 (Direct).
- Option exercise/conversion: disposed of 27,584 Non-Qualified Stock Option (right to buy) on August 27, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $19,207,098 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Robert Iannone — Officer (EVP, Global Head of R&D & CMO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-27 | Option exercise/conversion | Ordinary Shares | 26,116 | $113 | $3.0M | 111,223 |
| 2026-08-27 | Option exercise/conversion | Ordinary Shares | 884 | $113 | $100.0K | 112,107 |
| 2026-08-27 | Option exercise/conversion | Ordinary Shares | 27,584 | $137 | $3.8M | 139,691 |
| 2026-08-27 | Option exercise/conversion | Ordinary Shares | 2,916 | $137 | $399.8K | 142,607 |
| 2026-08-27 | Open-market sale | Ordinary Shares | 18,187 | $248 | $4.5M | 124,420 |
| 2026-08-27 | Open-market sale | Ordinary Shares | 11,423 | $249 | $2.8M | 112,997 |
| 2026-08-27 | Open-market sale | Ordinary Shares | 18,113 | $250 | $4.5M | 94,884 |
| 2026-08-27 | Open-market sale | Ordinary Shares | 19,639 | $251 | $4.9M | 75,245 |
| 2026-08-27 | Open-market sale | Ordinary Shares | 9,259 | $252 | $2.3M | 65,986 |
| 2026-08-27 | Open-market sale | Ordinary Shares | 300 | $253 | $75.8K | 65,686 |
| 2026-08-27 | Option exercise/conversion | Incentive Stock Option (right to buy) | 884 | — | — | 0 |
| 2026-08-27 | Option exercise/conversion | Incentive Stock Option (right to buy) | 2,916 | — | — | 0 |
| 2026-08-27 | Option exercise/conversion | Non-Qualified Stock Option (right to buy) | 26,116 | — | — | 0 |
| 2026-08-27 | Option exercise/conversion | Non-Qualified Stock Option (right to buy) | 27,584 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-27 | Option exercise/conversion (26,116 shares) |
| 2026-08-27 | Option exercise/conversion (884 shares) |
| 2026-08-27 | Option exercise/conversion (27,584 shares) |
| 2026-08-27 | Option exercise/conversion (2,916 shares) |
| 2026-08-27 | Open-market sale (18,187 shares) |
| 2026-08-27 | Open-market sale (11,423 shares) |
| 2026-08-27 | Open-market sale (18,113 shares) |
| 2026-08-27 | Open-market sale (19,639 shares) |
| 2026-08-27 | Open-market sale (9,259 shares) |
| 2026-08-27 | Open-market sale (300 shares) |
| 2026-08-27 | Option exercise/conversion (884 shares) |
| 2026-08-27 | Option exercise/conversion (2,916 shares) |
| 2026-08-27 | Option exercise/conversion (26,116 shares) |
| 2026-08-27 | Option exercise/conversion (27,584 shares) |
Keywords
insider transaction, Form 4, JAZZ, Jazz Pharmaceuticals plc, bearish, Robert Iannone
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.